Navigation Links
Susan G. Komen for the Cure(R) and Triple Negative Breast Cancer Foundation Unite to Fight Aggressive Form of Breast Cancer

Partnership Will Fund Breakthrough Research to Support the Discovery of Promising New Treatments for TNBC Patients

DALLAS, Jan. 12 /PRNewswire/ -- When her doctor told her she had breast cancer, Sonja Draught thought detecting it early had greatly enhanced her odds of living because that is the case for most forms of cancer. But then she learned she was battling a rare and aggressive form of the disease: triple negative breast cancer.


"When I was first diagnosed with breast cancer, I immediately thought early detection had really saved my life. Then I was told I had the 'bad' cancer," said Draught of Warren, Ohio. "I immediately thought how can all this research, awareness and donations be going to breast cancer and I'm being told my prognosis is bad at stage 1?"

To help women like Draught, Susan G. Komen for the Cure(R) announced it is teaming up with the Triple Negative Breast Cancer Foundation (TNBCF) to fund breakthrough life-saving research about this form of the disease.

At the recent Triple Negative Breast Cancer Symposium in San Antonio, Hala Moddelmog, Komen for the Cure president and CEO, along with Hayley Dinerman, TNBCF director of operations and Allison Axenrod, TNBCF executive director, signed an agreement to help launch The Susan G. Komen for the Cure Promise Grant Co-Funded by the Triple Negative Breast Cancer Foundation.

"This type of research is exactly what we've been looking for," said Dinerman. "By co-funding a Promise Grant with Susan G. Komen for the Cure, we can be certain that the project chosen will be an important, multi-faceted, multi-institutional triple negative-specific research initiative with real world clinical impact."

TNBCF's initial $500,000 contribution marks the first time a nonprofit partner has co-funded one of Komen's groundbreaking Promise Grants. Worth $7.5 million over five years, Promise Grants are designed to bring clinical researchers and basic scientists together to deliver new treatments for patients as quickly as possible.

To date, doctors know that most breast cancers are characterized by the presence of three receptors (proteins found inside or on the surface of breast cells): estrogen, progesterone and HER2. These receptors are not "expressed" in women with triple negative breast cancer - hence the name. Since most treatments available today are aimed at those receptors, TNBC is difficult to treat, and the tumors are often more aggressive. TNBC represents only 15 percent of all breast cancer cases but accounts for as many as 25 percent of all breast cancer deaths.

To accelerate our understanding of this rare form of the disease, a "think tank" of 31 researchers from leading cancer institutions worldwide was convened by Komen and TNBCF at the symposium in December.

Led by Dr. Eric Winer, Komen chief scientific advisor and TNBCF advisory board member, as well as Drs. Lisa Carey and George Sledge, also of the TNBCF advisory board, the symposium focused on topics ranging from how well TNBC responds to traditional chemotherapy to the unique ways TNBC spreads through the body.

"This unprecedented partnership with TNBCF is critical in the drive to better understand this difficult-to-treat type of breast cancer," Moddelmog said. "The more resources we devote to triple negative breast cancer, the sooner we'll find a cure."

About Susan G. Komen for the Cure(R)

Nancy G. Brinker promised her dying sister, Susan G. Komen, she would do everything in her power to end breast cancer forever. In 1982, that promise became Susan G. Komen for the Cure and launched the global breast cancer movement. Today, Komen for the Cure is the world's largest grassroots network of breast cancer survivors and activists fighting to save lives, empower people, ensure quality care for all and energize science to find the cures. Thanks to events like the Komen Race for the Cure(R), we have invested more than $1.2 billion to fulfill our promise, becoming the largest source of nonprofit funds dedicated to the fight against breast cancer in the world. For more information about Susan G. Komen for the Cure, breast health or breast cancer, visit or call 1-877 GO KOMEN.

About Triple Negative Breast Cancer Foundation

Launched in 2006 in honor of Nancy Block-Zenna, a young woman who was diagnosed at age 35 with triple negative breast cancer and died less than three years later, the Triple Negative Breast Cancer Foundation focuses on raising awareness and supporting research to find a cure for the disease. For more information about the Triple Negative Breast Cancer Foundation or triple negative breast cancer, visit or call 646-942-0242.

SOURCE Susan G. Komen for the Cure
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Susan Knapp Pinnas Named AvMed Health Plans New Senior Vice President of Network
2. Dr. Susan Lark's Squalane Now Made From Olives, Not Sharks
3. Susan Lark, MD Urges Women to Fight for Their Right to Use Bioidentical Hormones
4. Susan G. Komen for the Cure(R) Advocacy Alliance Applauds Selection of Senator Tom Daschle for HHS Secretary, White House Health Reform Czar
5. Susan G. Komen for the Cure(R) Announces Recipients of 2008 Komen Brinker Award for Scientific Distinction
6. ASH Honors Speaker of the House Nancy Pelosi and NHLBI Deputy Director Susan Shurin, MD, for Their Public Service, Leadership, and Commitment to Biomedical Research
7. Susan Lark, MD Speaks Out Against the Newest Osteoporosis Drug, Reclast
8. The Honorable Edward M. Kennedy, Scientists Mina J. Bissell and Susan Band Horwitz, and Philanthropist Jon M. Huntsman to Receive American Cancer Society Highest Honor for Outstanding Contributions to Cancer Fight
9. Susan G. Komen for the Cure(R) Hosts Inaugural Illinois State Summit in Springfield
10. Seva Foundation Recognizes Paul Courtright and Susan Lewallen for Their Commitment to Blindness Prevention
11. Samsung and Susan G. Komen for the Cure(R) Launch Historic Breast Cancer Alliance
Post Your Comments:
(Date:11/25/2015)... ... November 25, 2015 , ... “While riding the bus, I ... Bronx, N.Y. “I thought there had to be a convenient and comfortable way to ... The PROTECTOR enables disabled individuals to safely travel during cold or inclement weather. In ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... (PHA) announces the nation’s Periwinkle Pioneers, individuals and groups responsible for advancing care ... disease. The Periwinkle Pioneers, nominated by the public, will receive special recognition throughout ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... philanthropic seniors, is resulting in a way for homeless people to have a ... have launched a new initiative whereby they are repurposing plastic bags into sleeping ...
(Date:11/25/2015)... ... November 25, 2015 , ... Since its launch in 2012, ... adult stem cell therapies to patients with chronic degenerative medical conditions. Now, the ... Registered Trademark (RTM). , Organizations are required to hold a registered trademark in ...
(Date:11/24/2015)... ... November 25, 2015 , ... Genesis Chiropractic Software ... software creates an agreement between the practice owner and the patient that automatically ... notification, and projections. Click here to learn more. , ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... FRANCISCO , Nov. 24, 2015  Thanks to ... Dignity Health St. Mary,s Medical Center,s Sister Diane Grassilli ... breast imaging capabilities in San Francisco ... an anonymous friend, stepped forward with a gift of ... for Breast Digital Mammography with Tomosynthesis and Whole Breast ...
(Date:11/24/2015)... Colo. , Nov. 24, 2015  Array ... that its Chief Executive Officer, Ron Squarer ... Healthcare Conference in New York.  The public is ... webcast on the Array BioPharma website.Event:Piper Jaffray Annual ... , Wednesday, December 2, 2015Time:1:30 p.m. Eastern Time ...
(Date:11/24/2015)... HOUSTON, TX and VANCOUVER, Nov. 24, 2015 /PRNewswire/ ... EPI; NASDAQ: EPIX ) announced today that the ... clinical study of EPI-506 as a treatment for metastatic ... States and Canada.  --> ... --> In the Phase 1/2 clinical trial, ...
Breaking Medicine Technology: